Targeted systemic delivery of siRNA to cervical cancer model using cyclic RGD-installed unimer polyion complex-assembled gold nanoparticles

J Control Release. 2016 Dec 28;244(Pt B):247-256. doi: 10.1016/j.jconrel.2016.08.041. Epub 2016 Aug 30.

Abstract

For systemic delivery of small interfering RNA (siRNA) to solid tumors, we developed an actively-targeted unimer polyion complex-assembled gold nanoparticle (uPIC-AuNP) by a two-step assembling process. First is the monodispersed uPIC formation from the single molecules of therapeutic siRNA and the block catiomer, cyclic RGD (cRGD) peptide-installed poly(ethylene glycol)-block-poly(l-lysine) modified with lipoic acid (LA) at the ω-end (cRGD-PEG-PLL-LA). Second is the surface decoration of a 20nm-sized AuNP with uPICs. The cRGD-installed uPIC-AuNPs (cRGD-uPIC-AuNP) provided the targetability for selective binding to the cancer and cancer-related endothelial cellular surface, while regulating their size <50nm with a quite narrow distribution. The targeting efficacy of the cRGD-uPIC-AuNP was confirmed by in vitro cellular uptake in cultured cervical cancer (HeLa) cells and in vivo tumor accumulation in a subcutaneous HeLa model after systemic administration, compared with a non-targeted control uPIC-AuNP. Due to the targetability of the ligand, the cRGD-uPIC-AuNP achieved the significantly enhanced gene silencing ability in the subcutaneous HeLa tumor. Ultimately, the systemic delivery of siRNA targeted for papilloma virus-derived E6 oncogene by cRGD-uPIC-AuNP significantly inhibited the growth of subcutaneous HeLa tumor. This research demonstrates that the bottom-up construction of nanocarriers using monodispersed building blocks can be employed as delivery platforms for RNA interference-based cancer therapy.

Keywords: Cancer therapy; Gold nanoparticle; Unimer polyion complex; cRGD peptide; siRNA delivery.

MeSH terms

  • Animals
  • DNA-Binding Proteins / genetics
  • Female
  • Gold / administration & dosage*
  • Gold / chemistry
  • Gold / pharmacokinetics
  • Gold / therapeutic use
  • HeLa Cells
  • Humans
  • Metal Nanoparticles / administration & dosage*
  • Metal Nanoparticles / chemistry
  • Metal Nanoparticles / therapeutic use
  • Mice, Inbred BALB C
  • Mice, Nude
  • Oncogene Proteins, Viral / genetics
  • Peptides, Cyclic / administration & dosage*
  • Peptides, Cyclic / chemistry
  • Peptides, Cyclic / pharmacokinetics
  • Peptides, Cyclic / therapeutic use
  • Polyethylene Glycols / administration & dosage
  • Polyethylene Glycols / chemistry
  • Polyethylene Glycols / pharmacokinetics
  • Polyethylene Glycols / therapeutic use
  • RNA, Small Interfering / administration & dosage*
  • RNA, Small Interfering / chemistry
  • RNA, Small Interfering / pharmacokinetics
  • RNA, Small Interfering / therapeutic use
  • Thioctic Acid / administration & dosage
  • Thioctic Acid / chemistry
  • Thioctic Acid / pharmacokinetics
  • Thioctic Acid / therapeutic use
  • Tumor Burden / drug effects
  • Uterine Cervical Neoplasms / metabolism
  • Uterine Cervical Neoplasms / pathology
  • Uterine Cervical Neoplasms / therapy*

Substances

  • DNA-Binding Proteins
  • E6 protein, Human papillomavirus type 18
  • Oncogene Proteins, Viral
  • Peptides, Cyclic
  • RNA, Small Interfering
  • cyclic arginine-glycine-aspartic acid peptide
  • monomethoxypolyethyleneglycol-polylactide block copolymer
  • Polyethylene Glycols
  • Thioctic Acid
  • Gold